Objectives: The effects of hypercapnia on regional cerebral oxygen saturation (rSO) during surgery are unclear. We conducted a randomised controlled trial to investigate the relationship between mild hypercapnia and rSO. We hypothesised that, compared with targeted normocapnia (TN), targeted mild hypercapnia (TMH) during major surgery would increase rSO.
Design: A prospective, randomised, controlled trial in adult participants undergoing elective major surgery.
Setting: A single tertiary centre in Heidelberg, Victoria, Australia.
Participants: 40 participants were randomised to either a TMH or TN group (20 to each).
Interventions: TMH (partial pressure of carbon dioxide in arterial blood, PaCO, 45-55 mm Hg) or TN (PaCO 35-40 mm Hg) was delivered via controlled ventilation throughout surgery.
Primary And Secondary Outcome Measures: The primary endpoint was the absolute difference between the two groups in percentage change in rSO from baseline to completion of surgery. Secondary endpoints included intraoperative pH, bicarbonate concentration, base excess, serum potassium concentration, incidence of postoperative delirium and length of stay (LOS) in hospital.
Results: The absolute difference between the two groups in percentage change in rSO from the baseline to the completion of surgery was 19.0% higher in both hemispheres with TMH (p<0.001). On both sides, the percentage change in rSO was greater in the TMH group than the TN group throughout the duration of surgery. The difference between the groups became more noticeable over time. Furthermore, postoperative delirium was higher in the TN group (risk difference 0.3, 95% CI 0.1 to 0.5, p=0.02). LOS was similar between groups (5 days vs 5 days; p=0.99).
Conclusion: TMH was associated with a stable increase in rSO from the baseline, while TN was associated with a decrease in rSO in both hemispheres in patients undergoing major surgery. This resulted in a clear separation of percentage change in rSO from the baseline between TMH and TN over time. Our findings provide the rationale for larger studies on TMH during surgery.
Trial Registration Number: The Australian New Zealand Clinical Trials Registry (ACTRN12616000320459).
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7045198 | PMC |
| http://dx.doi.org/10.1136/bmjopen-2019-029159 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Social Media Potential and Impact on Changing Behaviors and Actions in Skin Health Promotion: Systematic Review.
J Med Internet Res
January 2025
Department of Education and Research in Health Sciences, Faculty of Health Sciences, Medical University of Warsaw, Warsaw, Poland.
Background: Social media is used as a tool for information exchange, entertainment, education, and intervention. Intervention efforts attempt to engage users in skin health.
Objective: This review aimed to collect and summarize research assessing the impact of social media on skin health promotion activities undertaken by social media users.
An Acetylcholine M1 Receptor-Positive Allosteric Modulator (TAK-071) in Parkinson Disease With Cognitive Impairment: A Phase 2 Randomized Clinical Trial.
JAMA Neurol
January 2025
Takeda Development Center Americas, Inc, Cambridge, Massachusetts.
Importance: Fall risk and cognitive impairment are prevalent and burdensome in Parkinson disease (PD), requiring efficacious, well-tolerated treatment.
Objective: To evaluate the safety and efficacy of TAK-071, a muscarinic acetylcholine M1 positive allosteric modulator, in participants with PD, increased fall risk, and cognitive impairment.
Design, Setting, And Participants: This phase 2 randomized double-blind placebo-controlled crossover clinical trial was conducted from October 21, 2020, to February 27, 2023, at 19 sites in the US.
Oxytocin versus carbetocin at elective Cesarean delivery in parturients with class III obesity: a double-blind randomized controlled noninferiority trial.
Can J Anaesth
January 2025
Department of Anesthesia and Pain Management, Mount Sinai Hospital, Mount Sinai Toronto, ON, Canada.
Purpose: Class III obesity (body mass index [BMI] ≥ 40 kg·m) is associated with high rates of Cesarean deliveries and postpartum hemorrhage, with increased maternal and fetal morbidity. The doses of oxytocin and carbetocin are two to four times higher at Cesarean delivery in patients with class III obesity. We sought to investigate the efficacy of carbetocin 80 µg iv compared with oxytocin 1 IU iv (plus infusion) at elective Cesarean delivery in parturients with class III obesity.
View Article and Find Full Text PDFDigital cognitive training for functionality in mild cognitive impairment: a randomized controlled clinical trial.
Geroscience
January 2025
Instituto de Ciências Biomédicas, Universidade Federal Do Rio de Janeiro, Rio de Janeiro, Brazil.
Digital cognitive training may improve cognition in people with mild cognitive impairment (MCI); however, the effect on functionality remains poorly defined. The Canadian Occupational Performance Measure (COPM) is a valid and consistent instrument for evaluating the performance of activities of daily living in this population. This study used the COPM to investigate the effects of digital cognitive training on functionality in individuals with MCI.
View Article and Find Full Text PDFUse of Cardioprotective Adjuncts in Type 1 Diabetes.
Diabetes Ther
January 2025
Garvan Institute of Medical Research, 384 Victoria St, Darlinghurst, NSW, 2010, Australia.
Type 1 diabetes is associated with excess cardiovascular risk, even after accounting for traditional cardiovascular risk factors, including glycaemia. Hence, there is an urgent need to document the metabolic abnormalities that contribute to the cardiovascular mortality gap in type 1 diabetes, and to examine whether cardioprotective type 2 diabetes medications prevent premature morbidity and mortality in this population.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!